Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
Anthony A. Portale(University of California, San Francisco), Karl Insogna(Children's Hospital at Westmead), Thomas O. Carpenter(Harvard University), Robin Lachmann(University College London), Hae II Cheong(Seoul National University Children's Hospital), Karine Briot, Erik A. Imel(Indiana University – Purdue University Indianapolis), Rachel Crowley(St. Vincent's University Hospital), Han‐Wook Yoo(CHA University Bundang Medical Center), Farzana Perwad(University of California, San Francisco), Christina Theodore‐Oklota(Ultragenyx Pharmaceutical (United States)), Thomas J. Weber(Duke Medical Center), Stuart H. Ralston(University of Edinburgh), Yasuhiro Takeuchi(University College London), Takuo Kubota(Osaka University Hospital), Martine Cohen‐Solal(Université Paris Cité), Maria Luisa Brandi, Nobuaki Ito(University of Tokyo Hospital), Richard Keen(Royal National Orthopaedic Hospital), Steven Ing(The Ohio State University Wexner Medical Center), Yasuo Imanishi(Osaka City University), Richard Eastell(University of Sheffield), M K Javaid(Southampton General Hospital), Javier San Martín(Amgen (United States)), Pisit Pitukcheewanont(Children's Hospital of Los Angeles), Peter Kamenický(Université Paris-Sud), Lin Zhang(Ultragenyx Pharmaceutical (United States)), Suzanne M. Jan de Beur(Johns Hopkins University), Hiroyuki Tanaka(Okayama Saiseikai General Hospital), Matt Mealiffe(Ultragenyx Pharmaceutical (United States))
Cited by 160
Related Papers
Clinician’s Guide to Prevention and Treatment of Osteoporosis
|Osteoporosis International|2014|4.1k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k